Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACI Formulations's Operating Income for the
three
months ended in Mar. 2026 was BDT145 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was BDT650 Mil.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
ACI Formulations's annualizedROC % for the quarter that ended in Mar. 2026 was 5.83%.
ACI Formulations's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.36%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
ACI Formulations Operating Income Related Terms
ACI Formulations Operating Income Historical Data
* Premium members only.
The historical data trend for ACI Formulations's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT650 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACI Formulations (DHA:ACIFORMULA) has a Operating Income of BDT650 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on ACI Formulations and its competitors.
Is ACI Formulations' Operating Income too high?
ACI Formulations' current Operating Income is BDT650 Mil. Overall, ACI Formulations has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACI Formulations' Operating Income compare to CTVA and CF?
ACI Formulations' Operating Income of BDT650 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for an Agriculture company?
A good Operating Income depends on the Agriculture industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on ACI Formulations and its competitors. ACI Formulations's current Operating Income is BDT650 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACI Formulations stock overvalued right now?
Based on GuruFocus' analysis, ACI Formulations (DHA:ACIFORMULA) is currently considered Fairly Valued. The stock's GF Value™ is BDT150.73, compared to a current price of BDT152.70 — trading 1.3% above its estimated fair value. The current Operating Income is BDT650 Mil. ACI Formulations' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For ACI Formulations (DHA:ACIFORMULA), the current Operating Income is BDT650 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACI Formulations (DHA:ACIFORMULA) Overvalued in 2026?
Based on GuruFocus' analysis, ACI Formulations stock appears to be overvalued.
The current stock price of BDT152.70 is trading 1.3% above its estimated GF Value™ of BDT150.73.
GuruFocus considers ACI Formulations to be Fairly Valued.
Key valuation signals for DHA:ACIFORMULA:
Operating Income: BDT650 Mil
GF Value™: BDT150.73 vs. price of BDT152.70 (1.3% above fair value)
No single metric tells the full story. See the DHA:ACIFORMULA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACI Formulations PLC is engaged in the manufacturing and marketing of several agrochemical and consumer products. The company offers a complete range of cost-effective solutions for farmers through formulating and marketing insecticides, herbicides, fungicides, miticides, etc. Its businesses are Pharmaceuticals, Salt, Skincare & Antiseptics, Kitchen Care, Fabric Care, Surface Care, Herbal Care, Lavatory Care, and Others. The group's reportable segments are Crop Care and Public Health (CC & PH), which include manufacturing and selling crop care and public health products; Mosquito coil (M. Coil) includes manufacturing and selling mosquito coil products; Aerosol provides manufacturing and selling aerosol and air freshener products; and Paint covers manufacture and sell paint products.
91GF Score
Get the complete analysis for DHA:ACIFORMULA
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACIFORMULA has been successfully added to your 
